Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder

Human Psychopharmacology

Volumn 30, Issue 6, 2015, Pages 393-415

  Bandelow, Borwin ^a   Wedekind, Dirk ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

antisocial personality disorder; borderline personality disorder; endogenous opioid system; reward system

Indexed keywords

ENDORPHIN; NALMEFENE; NALOXONE; NALTREXONE; OPIATE RECEPTOR; OPIATE PEPTIDE;

AGGRESSION; ANTISOCIAL BEHAVIOR; ANTISOCIAL PERSONALITY DISORDER; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CRIMINAL BEHAVIOR; DISSOCIATION; DOPAMINE RELEASE; DSM-5; DYSPHORIA; FEMALE; HUMAN; IMPULSIVENESS; IRRITABILITY; LIBIDO; MALE; NEUROBIOLOGY; NEUROPSYCHOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; REWARD; SENSATION SEEKING; SEXUAL BEHAVIOR; VENTRAL TEGMENTUM; ANIMAL; BORDERLINE STATE; METABOLISM; PATHOPHYSIOLOGY; PRISONER; PSYCHOLOGY;

AGGRESSION; ANIMALS; ANTISOCIAL PERSONALITY DISORDER; BORDERLINE PERSONALITY DISORDER; FEMALE; HUMANS; MALE; OPIOID PEPTIDES; PRISONERS; RECEPTORS, OPIOID; REWARD;

EID: 84947033465     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2497     Document Type: Article

References (304)

1. Adi Y, Juarez-Garcia A, Wang D, et al,. 2007. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 11 (6): iii-iv, 1-85.
2. de Almeida RM, Miczek KA,. 2002. Aggression escalated by social instigation or by discontinuation of reinforcement ("frustration") in mice: inhibition by anpirtoline: a 5-HT1B receptor agonist. Neuropsychopharmacology 27 (2): 171-181.
3. Alpay Ates M, Algul A, Semiz UB, et al., 2011. Clinical characteristics of self-mutilating behavior in Turkish male subjects with antisocial personality disorder: relationship to psychopathy. Int J Soc Psychiatry 57 (3): 237-247.
4. Amad A, Ramoz N, Thomas P, Jardri R, Gorwood P,. 2014. Genetics of borderline personality disorder: systematic review and proposal of an integrative model. Neurosci Biobehav Rev 40: 6-19.
5. Anton RF, Pettinati H, Zweben A, et al., 2004. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24 (4): 421-428.
6. Anton ME, Baskin-Sommers AR, Vitale JE, Curtin JJ, Newman JP,. 2012. Differential effects of psychopathy and antisocial personality disorder symptoms on cognitive and fear processing in female offenders. Cogn Affect Behav Neurosci 12 (4): 761-776.
7. APA. 2013. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5™). American Psychiatric Association: Washington, DC.
8. Aron A, Fisher H, Mashek DJ, Strong G, Li H, Brown LL,. 2005. Reward, motivation, and emotion systems associated with early-stage intense romantic love. J Neurophysiol 94 (1): 327-337.
9. Baik JH,. 2013. Dopamine signaling in reward-related behaviors. Front Neural Circ 7: 152.
10. Bandelow B, Krause J, Wedekind D, Broocks A, Hajak G, Ruther E,. 2005. Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res 134 (2): 169-179.
11. Bandelow B, Schmahl C, Falkai P, Wedekind D,. 2010. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev 117 (2): 623-636.
12. Barbano MF, Cador M,. 2007. Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology (Berl) 191 (3): 497-506.
13. Barkataki I, Kumari V, Das M, Taylor P, Sharma T,. 2006. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav Brain Res 169 (2): 239-247.
14. Barr CS, Schwandt ML, Lindell SG, et al., 2008. Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc Natl Acad Sci U S A 105 (13): 5277-5281.
15. Barrash J, Tranel D, Anderson SW,. 2000. Acquired personality disturbances associated with bilateral damage to the ventromedial prefrontal region. Dev Neuropsychol 18 (3): 355-381.
16. Beauchaine TP, Klein DN, Crowell SE, Derbidge C, Gatzke-Kopp L,. 2009. Multifinality in the development of personality disorders: a Biology × Sex × Environment interaction model of antisocial and borderline traits. Dev Psychopathol 21 (3): 735-770.
17. Beaver KM, Nedelec JL, Rowland MW, Schwartz JA,. 2012. Genetic risks and ADHD symptomatology: exploring the effects of parental antisocial behaviors in an adoption-based study. Child Psychiatry Hum Dev 43 (2): 293-305.
18. Berger P, Berner W, Bolterauer J, Gutierrez K, Berger K,. 1999. Sadistic personality disorder in sex offenders: relationship to antisocial personality disorder and sexual sadism. J Pers Disord 13 (2): 175-186.
19. Berridge KC, Aldridge JW,. 2008. Decision utility, the brain, and pursuit of hedonic goals. Soc Cognit 26 (5): 621-646.
20. Biederman J, Petty CR, Monuteaux MC, et al., 2010. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 167 (4): 409-417.
21. Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV,. 2012. Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study. J Clin Psychiatry 73 (7): 941-950.
22. Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C,. 2006a. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 25 (1): CD005653.
23. Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C,. 2006b. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 25 (1): CD005652.
24. Bjork JM, Chen G, Smith AR, Hommer DW,. 2010. Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescents. J Child Psychol Psychiatry 51 (7): 827-837.
25. Bjork JM, Chen G, Hommer DW,. 2012. Psychopathic tendencies and mesolimbic recruitment by cues for instrumental and passively obtained rewards. Biol Psychol 89 (2): 408-415.
26. Black DW, Baumgard CH, Bell SE,. 1995. A 16- to 45-year follow-up of 71 men with antisocial personality disorder. Compr Psychiatry 36 (2): 130-140.
27. Black DW, Gunter T, Allen J, et al., 2007. Borderline personality disorder in male and female offenders newly committed to prison. Compr Psychiatry 48 (5): 400-405.
28. Blair RJ,. 2008. The amygdala and ventromedial prefrontal cortex: functional contributions and dysfunction in psychopathy. Philos Trans R Soc Lond B Biol Sci 363 (1503): 2557-2565.
29. Bland RC, Newman SC, Orn H, Stebelsky G,. 1993. Epidemiology of pathological gambling in Edmonton. Can J Psychiatry 38 (2): 108-112.
30. Bloom JM, Woodward EN, Susmaras T, Pantalone DW,. 2012. Use of dialectical behavior therapy in inpatient treatment of borderline personality disorder: a systematic review. Psychiatr Serv 63 (9): 881-888.
31. Blum K, Gardner E, Oscar-Berman M, Gold M,. 2012. "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. Curr Pharm Des 18 (1): 113-118.
32. Bodnar RJ,. 2007. Endogenous opiates and behavior: 2006. Peptides 28 (12): 2435-2513.
33. Boecker H, Sprenger T, Spilker ME, et al., 2008. The runner's high: opioidergic mechanisms in the human brain. Cereb Cortex 18 (11): 2523-2531.
34. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, et al., 1999. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 60 (9): 598-603.
35. Bohus M, Limberger M, Ebner U, et al., 2000. Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior. Psychiatry Res 95 (3): 251-260.
36. Book AS, Quinsey VL, Langford D,. 2007. Psychopathy and the perception of affect and vulnerability. Crim Justice Behav 34 (4): 531-544.
37. Bostwick JM, Bucci JA,. 2008. Internet sex addiction treated with naltrexone. Mayo Clin Proc 83 (2): 226-230.
38. Brambilla P, Soloff PH, Sala M, Nicoletti MA, Keshavan MS, Soares JC,. 2004. Anatomical MRI study of borderline personality disorder patients. Psychiatry Res 131 (2): 125-133.
39. Bresin K, Gordon KH,. 2013. Endogenous opioids and nonsuicidal self-injury: a mechanism of affect regulation. Neurosci Biobehav Rev 37 (3): 374-383.
40. Brewer JA, Potenza MN,. 2008. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75 (1): 63-75.
41. Brodsky BS, Groves SA, Oquendo MA, Mann JJ, Stanley B,. 2006. Interpersonal precipitants and suicide attempts in borderline personality disorder. Suicide Life Threat Behav 36 (3): 313-322.
42. Brody S, Potterat JJ, Muth SQ, Woodhouse DE,. 2005. Psychiatric and characterological factors relevant to excess mortality in a long-term cohort of prostitute women. J Sex Marital Ther 31 (2): 97-112.
43. Brook M, Kosson DS,. 2013. Impaired cognitive empathy in criminal psychopathy: evidence from a laboratory measure of empathic accuracy. J Abnorm Psychol 122 (1): 156-166.
44. Brook M, Brieman CL, Kosson DS,. 2013. Emotion processing in Psychopathy Checklist-assessed psychopathy: a review of the literature. Clin Psychol Rev 33 (8): 979-995.
45. Brunner HG, Nelen MR, van Zandvoort P, et al., 1993. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 52 (6): 1032-1039.
46. Buckholtz JW, Meyer-Lindenberg A,. 2008. MAOA and the neurogenetic architecture of human aggression. Trends Neurosci 31 (3): 120-129.
47. Buckholtz JW, Treadway MT, Cowan RL, et al., 2010. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci 13 (4): 419-421.
48. Bullock K, Koran L,. 2003. Psychopharmacology of compulsive buying. Drugs Today (Barc) 39 (9): 695-700.
49. Burke JD, Stepp SD,. 2012. Adolescent disruptive behavior and borderline personality disorder symptoms in young adult men. J Abnorm Child Psychol 40 (1): 35-44.
50. Cahill BS, Coolidge FL, Segal DL, Klebe KJ, Marle PD, Overmann KA,. 2012. Prevalence of ADHD and its subtypes in male and female adult prison inmates. Behav Sci Law 30 (2): 154-166.
51. Carpenter RW, Wood PK, Trull TJ,. 2015. Comorbidity of borderline personality disorder and lifetime substance use disorders in a nationally representative sample. J Pers Disord 20: 1-15.
52. Carr KD,. 1996. Feeding, drug abuse, and the sensitization of reward by metabolic need. Neurochem Res 21 (11): 1455-1467.
53. Caspi A, McClay J, Moffitt TE, et al., 2002. Role of genotype in the cycle of violence in maltreated children. Science 297 (5582): 851-854.
54. Chanen AM, Velakoulis D, Carison K, et al., 2008. Orbitofrontal, amygdala and hippocampal volumes in teenagers with first-presentation borderline personality disorder. Psychiatry Res 163 (2): 116-125.
55. Chapman AL, Cellucci T,. 2007. The role of antisocial and borderline personality features in substance dependence among incarcerated females. Addict Behav 32 (6): 1131-1145.
56. Chatoor I, Herman BH, Hartzler J,. 1994. Effects of the opiate antagonist, naltrexone, on binging antecedents and plasma beta-endorphin concentrations. J Am Acad Child Adolesc Psychiatry 33 (5): 748-752.
57. Cleckley HM,. 1941. The Mask of Sanity: An Attempt to Reinterpret the So-Called Psychopathic Personality. The C. V. Mosby company: St. Louis.
58. Cloninger CR,. 1987. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44 (6): 573-588.
59. Coid J, Kahtan N, Gault S, Jarman B,. 1999. Patients with personality disorder admitted to secure forensic psychiatry services. Br J Psychiatry 175: 528-536.
60. Connor DF, Steeber J, McBurnett K,. 2010. A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr 31 (5): 427-440.
61. Couppis MH, Kennedy CH,. 2008. The rewarding effect of aggression is reduced by nucleus accumbens dopamine receptor antagonism in mice. Psychopharmacology (Berl) 197 (3): 449-456.
62. Creighton CJ, Ramabadran K, Ciccone PE, Liu J, Orsini MJ, Reitz AB,. 2004. Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect. Bioorg Med Chem Lett 14 (15): 4083-4085.
63. Curtin F, Niveau G,. 1998. Psychosocial profile of Swiss sexual offenders. J Forensic Sci 43 (4): 755-759.
64. Damasio H, Grabowski T, Frank R, Galaburda AM, Damasio AR,. 1994. The return of Phineas Gage: clues about the brain from the skull of a famous patient. Science 264 (5162): 1102-1105.
65. Darke S, Williamson A, Ross J, Teesson M, Lynskey M,. 2004. Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 74 (1): 77-83.
66. Darke S, Ross J, Williamson A, Teesson M,. 2005. The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction 100 (8): 1121-1130.
67. Davids E, Gastpar M,. 2005. Attention deficit hyperactivity disorder and borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 29 (6): 865-877.
68. Davidson RJ, Putnam KM, Larson CL,. 2000. Dysfunction in the neural circuitry of emotion regulation-a possible prelude to violence. Science 289 (5479): 591-594.
69. De La Fuente JM, Goldman S, Stanus E, et al., 1997. Brain glucose metabolism in borderline personality disorder. J Psychiatr Res 31 (5): 531-541.
70. De Vries TJ, Shippenberg TS,. 2002. Neural systems underlying opiate addiction. J Neurosci 22 (9): 3321-3325.
71. Decety J, Michalska KJ, Akitsuki Y, Lahey BB,. 2009. Atypical empathic responses in adolescents with aggressive conduct disorder: a functional MRI investigation. Biol Psychol 80 (2): 203-211.
72. Dell'Osso B, Berlin HA, Serati M, Altamura AC,. 2010. Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology 61 (4): 169-179.
73. Der-Avakian A, Markou A,. 2012. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35 (1): 68-77.
74. Dichter GS, Damiano CA, Allen JA,. 2012. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord 4 (1): 19.
75. Distel MA, Trull TJ, Derom CA, et al., 2008. Heritability of borderline personality disorder features is similar across three countries. Psychol Med 38 (9): 1219-1229.
76. Distel MA, Carlier A, Middeldorp CM, Derom CA, Lubke GH, Boomsma DI,. 2011. Borderline personality traits and adult attention-deficit hyperactivity disorder symptoms: a genetic analysis of comorbidity. Am J Med Genet B Neuropsychiatr Genet 156B (7): 817-825.
77. Dolan M,. 2012. The neuropsychology of prefrontal function in antisocial personality disordered offenders with varying degrees of psychopathy. Psychol Med 42 (8): 1715-1725.
78. Dolan M, Fullam R,. 2004. Theory of mind and mentalizing ability in antisocial personality disorders with and without psychopathy. Psychol Med 34 (6): 1093-1102.
79. Drobes DJ, Anton RF, Thomas SE, Voronin K,. 2004. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28 (9): 1362-1370.
80. Elbert T, Weierstall R, Schauer M,. 2010. Fascination violence: on mind and brain of man hunters. Eur Arch Psychiatry Clin Neurosci 260: S100-S105.
81. A receptors in the nucleus accumbens. Neuropsychopharmacology 39 (8): 1805-1815.
82. Enoch MA,. 2008. The role of GABA(A) receptors in the development of alcoholism. Pharmacol Biochem Behav 90 (1): 95-104.
83. Esch T, Stefano GB,. 2005. The neurobiology of love. Neuro Endocrinol Lett 26 (3): 175-192.
84. Faraone SV, Buitelaar J,. 2010. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19 (4): 353-364.
85. Fazel S, Danesh J,. 2002. Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet 359 (9306): 545-550.
86. Ferguson CJ,. 2010. Genetic contributions to antisocial personality and behavior: a meta-analytic review from an evolutionary perspective. J Soc Psychol 150 (2): 160-180.
87. Fernandez-Montalvo J, Echeburua E,. 2004. Pathological gambling and personality disorders: an exploratory study with the IPDE. J Pers Disord 18 (5): 500-505.
88. Fish EW, De Bold JF, Miczek KA,. 2002. Aggressive behavior as a reinforcer in mice: activation by allopregnanolone. Psychopharmacology (Berl) 163 (3-4): 459-466.
89. Fossati A, Novella L, Donati D, Donini M, Maffei C,. 2002. History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Compr Psychiatry 43 (5): 369-377.
90. Freestone M, Howard R, Coid JW, Ullrich S,. 2013. Adult antisocial syndrome co-morbid with borderline personality disorder is associated with severe conduct disorder, substance dependence and violent antisociality. Pers Ment Health 7 (1): 11-21.
91. van Gaalen MM, van Koten R, Schoffelmeer AN, Vanderschuren LJ,. 2006. Critical involvement of dopaminergic neurotransmission in impulsive decision making. Biol Psychiatry 60 (1): 66-73.
92. Gibbon S, Duggan C, Stoffers J, et al,. 2010. Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev (6): CD007668.
93. Glenn AL, Yang Y,. 2012. The potential role of the striatum in antisocial behavior and psychopathy. Biol Psychiatry 72 (10): 817-822.
94. Goethals I, Audenaert K, Jacobs F, et al., 2005. Brain perfusion SPECT in impulsivity-related personality disorders. Behav Brain Res 157 (1): 187-192.
95. Goldfarb AH, Jamurtas AZ,. 1997. Beta-endorphin response to exercise. An update. Sports Med 24 (1): 8-16.
96. Goldman SJ, D'Angelo EJ, DeMaso DR,. 1993. Psychopathology in the families of children and adolescents with borderline personality disorder. Am J Psychiatry 150 (12): 1832-1835.
97. Gorelick DA, Kim YK, Bencherif B, et al., 2005. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57 (12): 1573-1582.
98. Grafman J, Schwab K, Warden D, Pridgen A, Brown HR, Salazar AM,. 1996. Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology 46 (5): 1231-1238.
99. Grant JE, Kim SW,. 2001. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry 13 (4): 229-231.
100. Grant JE, Kim SW,. 2002. An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry 63 (4): 349-356.
101. Grant JE, Potenza MN, Hollander E, et al., 2006. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163 (2): 303-312.
102. Grant JE, Kim SW, Hartman BK,. 2008. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 69 (5): 783-789.
103. Grant JE, Kim SW, Odlaug BL,. 2009. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry 65 (7): 600-606.
104. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW,. 2010. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 197 (4): 330-331.
105. Gray JA,. 1987. Perspectives on anxiety and impulsivity-a commentary. J Res Pers 21 (4): 493-509.
106. Gregory S, Ffytche D, Simmons A, et al., 2012. The antisocial brain: psychopathy matters. Arch Gen Psychiatry 69 (9): 962-972.
107. Gunter TD, Vaughn MG, Philibert RA,. 2010. Behavioral genetics in antisocial spectrum disorders and psychopathy: a review of the recent literature. Behav Sci Law 28 (2): 148-173.
108. Guterstam J, Jayaram-Lindstrom N, Cervenka S, et al., 2012. Effects of amphetamine on the human brain opioid system-a positron emission tomography study. Int J Neuropsychopharmacol 16 (4): 1-7.
109. Haaland VO, Landro NI,. 2009. Pathological dissociation and neuropsychological functioning in borderline personality disorder. Acta Psychiatr Scand 119 (5): 383-392.
110. Hansen AL, Johnsen BH, Hart S, Waage L, Thayer JF,. 2008. Brief communication: psychopathy and recognition of facial expressions of emotion. J Pers Disord 22 (6): 639-644.
111. Hare RD,. 2003. Hare Psychopathy Checklist-Revised, 2nd edn. Multi Health Systems: Toronto, Ontario.
112. Hare RD, Neumann CS,. 2010. The role of antisociality in the psychopathy construct: comment on Skeem and Cooke (2010). Psychol Assess 22 (2): 446-454.
113. Hassan A, Bower JH, Kumar N, et al., 2011. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord 17 (4): 260-264.
114. Hatzitaskos P, Soldatos CR, Kokkevi A, Stefanis CN,. 1999. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Compr Psychiatry 40 (4): 278-282.
115. Heinz A, Reimold M, Wrase J, et al., 2005. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62 (1): 57-64.
116. Hennig J, Laschefski U, Opper C,. 1994. Biopsychological changes after bungee jumping: beta-endorphin immunoreactivity as a mediator of euphoria? Neuropsychobiology 29 (1): 28-32.
117. Herpers PCM, Scheepers FE, Bons DMA, Buitelaar JK, Rommelse NNJ,. 2013. The cognitive and neural correlates of psychopathy and especially callous-unemotional traits in youths: a systematic review of the evidence. Dev Psychopathol FirstView: 1-29.
118. Hill A, Habermann N, Berner W, Briken P,. 2007. Psychiatric disorders in single and multiple sexual murderers. Psychopathology 40 (1): 22-28.
119. Hirvonen J, Aalto S, Hagelberg N, et al., 2009. Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging 36 (2): 275-286.
120. Hodgins S, De Brito SA, Chhabra P, Cote G,. 2010. Anxiety disorders among offenders with antisocial personality disorders: a distinct subtype? Can J Psychiatry 55 (12): 784-791.
121. van Honk J, Schutter DJ,. 2006. Unmasking feigned sanity: a neurobiological model of emotion processing in primary psychopathy. Cogn Neuropsychiatry 11 (3): 285-306.
122. Howard R, Huband N, Duggan C,. 2012. Adult antisocial syndrome with comorbid borderline pathology: association with severe childhood conduct disorder. Ann Clin Psychiatry 24 (2): 127-134.
123. Hsu DT, Sanford BJ, Meyers KK, et al., 2013. Response of the mu-opioid system to social rejection and acceptance. Mol Psychiatry 18 (11): 1211-1217.
124. Huang J, He W, Chen W, Yu W, Shen M, Wang W,. 2011. The Zuckerman-Kuhlman Personality Questionnaire predicts functioning styles of personality disorder: a trial in healthy subjects and personality-disorder patients. Psychiatry Res 186 (2-3): 320-325.
125. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR,. 1975. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (5536): 577-580.
126. Huseman CA, Pearson PH, Madison J, Leuschen MP,. 1990. Bulimia as a form of self-addiction-treatment with naltrexone hydrochloride (Trexan)-a pilot study. Clin Trials J 27 (2): 77-83.
127. Hutchinson MR, Northcutt AL, Hiranita T, et al., 2012. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 32 (33): 11187-11200.
128. Ikemoto S, Wise RA,. 2004. Mapping of chemical trigger zones for reward. Neuropharmacology 47 (Suppl 1): 190-201.
129. Inch H, Huws R,. 1993. Tattooed female psychiatric patients. Br J Psychiatry 163: 127-128.
130. Ishikawa A, Ambroggi F, Nicola SM, Fields HL,. 2008. Dorsomedial prefrontal cortex contribution to behavioral and nucleus accumbens neuronal responses to incentive cues. J Neurosci 28 (19): 5088-5098.
131. Jayaram-Lindstrom N, Hammarberg A, Beck O, Franck J,. 2008. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165 (11): 1442-1448.
132. Johnson SW, North RA,. 1992. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12 (2): 483-488.
133. Jonas JM, Gold MS,. 1986. Treatment of antidepressant-resistant bulimia with naltrexone. Int J Psychiatry Med 16 (4): 305-309.
134. Joutsa J, Johansson J, Niemela S, et al., 2012. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage 60 (4): 1992-1999.
135. Jumper S, Babula M, Casbon T,. 2012. Diagnostic profiles of civilly committed sexual offenders in illinois and other reporting jurisdictions: what we know so far. Int J Offender Ther Comp Criminol 56 (6): 838-855.
136. Kalin NH, Shelton SE, Lynn DE,. 1995. Opiate systems in mother and infant primates coordinate intimate contact during reunion. Psychoneuroendocrinology 20 (7): 735-742.
137. Keating GM,. 2013. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 27 (9): 761-772.
138. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML,. 2005. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 58 (11): 843-853.
139. Kelley AE,. 2004. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44 (1): 161-179.
140. Kelley AE, Berridge KC,. 2002. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22 (9): 3306-3311.
141. Kennedy SE, Koeppe RA, Young EA, Zubieta JK,. 2006. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63 (11): 1199-1208.
142. Khalifa N, Duggan C, Stoffers J, et al,. 2010. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev 4 (8): CD007667.
143. Kiehl KA, Smith AM, Hare RD, et al., 2001. Limbic abnormalities in affective processing by criminal psychopaths as revealed by functional magnetic resonance imaging. Biol Psychiatry 50 (9): 677-684.
144. Kim SW, Grant JE,. 2001. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 16 (5): 285-289.
145. Kim SW, Grant JE, Adson DE, Shin YC,. 2001. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49 (11): 914-921.
146. Kjelsberg E, Winther M, Dahl AA,. 1995. Overdose deaths in young substance abusers: accidents or hidden suicides? Acta Psychiatr Scand 91 (4): 236-242.
147. Kleindienst N, Bohus M, Ludascher P, et al., 2008. Motives for nonsuicidal self-injury among women with borderline personality disorder. J Nerv Ment Dis 196 (3): 230-236.
148. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D,. 2001. Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 12 (17): 3683-3687.
149. Koenigs M, Baskin-Sommers A, Zeier J, Newman JP,. 2011. Investigating the neural correlates of psychopathy: a critical review. Mol Psychiatry 16 (8): 792-799.
150. Koepp MJ, Hammers A, Lawrence AD, Asselin MC, Grasby PM, Bench CJ,. 2009. Evidence for endogenous opioid release in the amygdala during positive emotion. Neuroimage 44 (1): 252-256.
151. Komaki G, Tamai H, Sumioki H, et al., 1990. Plasma beta-endorphin during fasting in man. Horm Res 33 (6): 239-243.
152. Koob GF,. 2013. Addiction is a reward deficit and stress surfeit disorder. Front Psychiatr 4: 72.
153. Kopp D, Spitzer C, Kuwert P, et al., 2009. Psychische Störungen und Kindheitstraumata bei Strafgefangenen mit antisozialer Persönlichkeitsstörung. Fortschr Neurol Psychiatr 77 (3): 152-159.
154. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS,. 2005. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8 (11): 1450-1457.
155. Kumari V, Gudjonsson GH, Raghuvanshi S, et al., 2013. Reduced thalamic volume in men with antisocial personality disorder or schizophrenia and a history of serious violence and childhood abuse. Eur Psychiatry 28 (4): 225-234.
156. Kumor K, Su TP, Vaupel B, Haertzen C, Johnson RE, Goldberg S,. 1986. Studies of kappa agonist. NIDA Res Monogr 67: 18-25.
157. Kunert HJ, Druecke HW, Sass H, Herpertz SC,. 2003. Frontal lobe dysfunctions in borderline personality disorder? Neuropsychological findings. J Pers Disord 17 (6): 497-509.
158. Kuruoglu AC, Arikan Z, Vural G, Karatas M, Arac M, Isik E,. 1996. Single photon emission computerised tomography in chronic alcoholism. Antisocial personality disorder may be associated with decreased frontal perfusion. Br J Psychiatry 169 (3): 348-354.
159. Laakso MP, Gunning-Dixon F, Vaurio O, Repo-Tiihonen E, Soininen H, Tiihonen J,. 2002. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism. Psychiatry Res 114 (2): 95-102.
160. Lawrence KA, Allen JS, Chanen AM,. 2010. Impulsivity in borderline personality disorder: reward-based decision-making and its relationship to emotional distress. J Pers Disord 24 (6): 786-799.
161. Le Merrer J, Becker JA, Befort K, Kieffer BL,. 2009. Reward processing by the opioid system in the brain. Physiol Rev 89 (4): 1379-1412.
162. LeGris J, van Reekum R,. 2006. The neuropsychological correlates of borderline personality disorder and suicidal behaviour. Can J Psychiatry 51 (3): 131-142.
163. Lever JR,. 2007. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr Pharm Des 13 (1): 33-49.
164. Lewis PA, Rezaie R, Brown R, Roberts N, Dunbar RI,. 2011. Ventromedial prefrontal volume predicts understanding of others and social network size. Neuroimage 57 (4): 1624-1629.
165. Livesley WJ, Jang KL, Jackson DN, Vernon PA,. 1993. Genetic and environmental contributions to dimensions of personality disorder. Am J Psychiatry 150 (12): 1826-1831.
166. Love TM, Stohler CS, Zubieta JK,. 2009. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry 66 (10): 1124-1134.
167. Loyd DR, Wang X, Murphy AZ,. 2008. Sex differences in micro-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia. J Neurosci 28 (52): 14007-14017.
168. Lykken DT,. 1995. The Antisocial Personalities. Psychology Press: Berkeley, CA.
169. Lynam DR, Vachon DD,. 2012. Antisocial personality disorder in DSM-5: missteps and missed opportunities. Pers Disord 3 (4): 483-495.
170. Machin AJ, Dunbar RIM,. 2011. The brain opioid theory of social attachment: a review of the evidence. Behaviour 148 (9-10): 985-1025.
171. Maes HH, Silberg JL, Neale MC, Eaves LJ,. 2007. Genetic and cultural transmission of antisocial behavior: an extended twin parent model. Twin Res Hum Genet 10 (1): 136-150.
172. Malone SM, Taylor J, Marmorstein NR, McGue M, Iacono WG,. 2004. Genetic and environmental influences on antisocial behavior and alcohol dependence from adolescence to early adulthood. Dev Psychopathol 16 (4): 943-966.
173. Mannuzza S, Klein RG, Moulton JL, III,. 2002. Young adult outcome of children with "situational" hyperactivity: a prospective, controlled follow-up study. J Abnorm Child Psychol 30 (2): 191-198.
174. Marini VA, Stickle TR,. 2010. Evidence for deficits in reward responsivity in antisocial youth with callous-unemotional traits. Pers Disord 1 (4): 218-229.
175. Marrazzi MA, Luby ED,. 1986. An auto-addiction opioid model of chronic anorexia nervosa. Int J Eat Disord 5: 191-208.
176. Marrazzi MA, Bacon JP, Kinzie J, Luby ED,. 1995. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol 10 (3): 163-172.
177. Martin-Soelch C, Leenders KL, Chevalley AF, et al., 2001. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev 36 (2-3): 139-149.
178. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB,. 1999. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56 (8): 719-724.
179. McGee MD,. 1997. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 58 (1): 32-33.
180. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, et al., 2006. Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci U S A 103 (16): 6269-6274.
181. Minton TD,. 2013. Jail Inmates at Midyear 2012-Statistical Tables. U.S. Department of Justice. Bureau of Justice Statistics: Washington, D.C.
182. Mishra S, Lalumiere ML, Morgan M, Williams RJ,. 2011. An examination of the relationship between gambling and antisocial behavior. J Gambl Stud 27 (3): 409-426.
183. Mitchell JE, Christenson G, Jennings J, et al., 1989. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 9 (2): 94-97.
184. Moffitt TE, Silva PA,. 1988. Self-reported delinquency, neuropsychological deficit, and history of attention deficit disorder. J Abnorm Child Psychol 16 (5): 553-569.
185. Moles A, Kieffer BL, D'Amato FR,. 2004. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 304 (5679): 1983-1986.
186. Morgan AB, Lilienfeld SO,. 2000. A meta-analytic review of the relation between antisocial behavior and neuropsychological measures of executive function. Clin Psychol Rev 20 (1): 113-136.
187. Mueller A, Muhlhans B, Silbermann A, et al., 2009. Compulsive buying and psychiatric comorbidity. Psychother Psychosom Med Psychol 59 (8): 291-299.
188. Naltrexone package insert. www.accessdata.fda.gov/drugsatfda-docs/label/2013/018932s017lbl.pdf
189. Narayanan S, Lam H, Christian L, et al., 2004. Endogenous opioids mediate basal hedonic tone independent of dopamine D-1 or D-2 receptor activation. Neuroscience 124 (1): 241-246.
190. Nestadt G, Eaton WW, Romanoski AJ, et al., 1994. Assessment of DSM-III personality structure in a general-population survey. Compr Psychiatry 35 (1): 54-63.
191. Nestler EJ,. 2005. The neurobiology of cocaine addiction. Sci Pract Perspect 3 (1): 4-10.
192. Norelli LJ, Smith HS, Sher L, Blackwood TA,. 2013. Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature. Int J Adolesc Med Health 25 (3): 323-330.
193. Nutt DJ,. 2014. The role of the opioid system in alcohol dependence. J Psychopharmacol 28 (1): 8-22.
194. Odent M,. 1999. The Scientification of Love. Free Association Books Limited: London.
195. Ogloff JR,. 2006. Psychopathy/antisocial personality disorder conundrum. Aust N Z J Psychiatry 40 (6-7): 519-528.
196. Öhlin L, Hesse M, Fridell M, Tatting P,. 2011. Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile. BMC Psychiatry 11: 81.
197. Olds J, Milner P,. 1954. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47 (6): 419-427.
198. Orihuela-Flores M, Deriaz N, Carminati GG,. 2010. Naltrexone in adults with intellectual disability improves compulsive and dissocial disorders: a case report. Prog Neuropsychopharmacol Biol Psychiatry 34 (6): 1137-1138.
199. Osuch E, Ford K, Wrath A, Bartha R, Neufeld R,. 2014. Functional MRI of pain application in youth who engaged in repetitive non-suicidal self-injury vs. psychiatric controls. Psychiatry Res.
200. Pajer K, Stouthamer-Loeber M, Gardner W, Loeber R,. 2006. Women with antisocial behaviour: long-term health disability and help-seeking for emotional problems. Crim Behav Ment Health 16 (1): 29-42.
201. Panksepp J, Herman B, Conner R, Bishop P, Scott JP,. 1978. The biology of social attachments: opiates alleviate separation distress. Biol Psychiatry 13 (5): 607-618.
202. Pape W, Woller W,. 2014. Low dose naltrexone in the treatment of dissociative symptoms. Nervenarzt 86 (3): 346-351.
203. Paris J,. 1997. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr Psychiatry 38 (4): 237-242.
204. Paris J,. 2003. Personality disorders over time: precursors, course and outcome. J Pers Disord 17 (6): 479-488.
205. Paris J, Zweig-Frank H,. 2001. A 27-year follow-up of patients with borderline personality disorder. Compr Psychiatry 42 (6): 482-487.
206. Paris J, Brown R, Nowlis D,. 1987. Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry 28 (6): 530-535.
207. Paris J, Zweig-Frank H, Guzder J,. 1994. Psychological risk factors for borderline personality disorder in female patients. Compr Psychiatry 35 (4): 301-305.
208. Paris J, Chenard-Poirier MP, Biskin R,. 2013. Antisocial and borderline personality disorders revisited. Compr Psychiatry 54 (4): 321-325.
209. Patrick CJ,. 2008. Psychophysiological correlates of aggression and violence: an integrative review. Phil Trans Roy Soc B Biol Sci 363 (1503): 2543-2555.
210. Peltopuro M, Ahonen T, Kaartinen J, Seppala H, Narhi V,. 2014. Borderline intellectual functioning: a systematic literature review. Intellect Dev Disabil 52 (6): 419-443.
211. Pert CB, Snyder SH,. 1973. Opiate receptor: demonstration in nervous tissue. Science 179 (4077): 1011-1014.
212. Petrovic P, Pleger B, Seymour B, et al., 2008. Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 28 (42): 10509-10516.
213. Petry NM,. 2002. Discounting of delayed rewards in substance abusers: relationship to antisocial personality disorder. Psychopharmacology (Berl) 162 (4): 425-432.
214. Pfaus JG, Damsma G, Nomikos GG, et al., 1990. Sexual behavior enhances central dopamine transmission in the male rat. Brain Res 530 (2): 345-348.
215. Philipsen A, Schmahl C, Lieb K,. 2004. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37 (5): 196-199.
216. Pietras CJ, Cherek DR, Lane SD, Tcheremissine OV, Steinberg JL,. 2003. Effects of methylphenidate on impulsive choice in adult humans. Psychopharmacology (Berl) 170 (4): 390-398.
217. Powell JL, Lewis PA, Dunbar RI, Garcia-Finana M, Roberts N,. 2010. Orbital prefrontal cortex volume correlates with social cognitive competence. Neuropsychologia 48 (12): 3554-3562.
218. Prossin AR, Love TM, Koeppe RA, Zubieta JK, Silk KR,. 2010. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 167 (8): 925-933.
219. Pujara M, Motzkin JC, Newman JP, Kiehl KA, Koenigs M,. 2013. Neural correlates of reward and loss sensitivity in psychopathy. Soc Cogn Affect Neurosci 9 (6): 794-801.
220. Quay HC,. 1993. The psychobiology of undersocialized aggressive conduct disorder-a theoretical perspective. Dev Psychopathol 5 (1-2): 165-180.
221. Rabiner E, Mick I, Jim M, et al., 2014. Dysregulation in the opioid system in pathological gambling: a [11C] carfentanil PET study. Neuropsychopharmacology 39: S205-S206.
222. Raine A, Lencz T, Bihrle S, LaCasse L, Colletti P,. 2000. Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry 57 (2): 119-127; discussion 128-9.
223. Raine A, Lencz T, Taylor K, et al., 2003. Corpus callosum abnormalities in psychopathic antisocial individuals. Arch Gen Psychiatry 60 (11): 1134-1142.
224. Raine A, Ishikawa SS, Arce E, et al., 2004. Hippocampal structural asymmetry in unsuccessful psychopaths. Biol Psychiatry 55 (2): 185-191.
225. Raine A, Yang Y, Narr KL, Toga AW,. 2011. Sex differences in orbitofrontal gray as a partial explanation for sex differences in antisocial personality. Mol Psychiatry 16 (2): 227-236.
226. Ravert HT, Bencherif B, Madar I, Frost JJ,. 2004. PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des 10 (7): 759-768.
227. Raymond NC, Grant JE, Kim SW, Coleman E,. 2002. Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies. Int Clin Psychopharmacol 17 (4): 201-205.
228. van Ree JM,. 1979. Reinforcing stimulus properties of drugs. Neuropharmacology 18 (12): 963-969.
229. Reese J, Kraschewski A, Anghelescu I, et al., 2010. Haplotypes of dopamine and serotonin transporter genes are associated with antisocial personality disorder in alcoholics. Psychiatr Genet 20 (4): 140-152.
230. Rhee SH, Waldman ID,. 2002. Genetic and environmental influences on antisocial behavior: a meta-analysis of twin and adoption studies. Psychol Bull 128 (3): 490-529.
231. Robins LN,. 1966. Deviant Children Grown Up. Williams & Wilkins: Baltimore, MD.
232. Rolls ET, Grabenhorst F,. 2008. The orbitofrontal cortex and beyond: from affect to decision-making. Prog Neurobiol 86 (3): 216-244.
233. Rossiter EM, Agras WS, Telch CF, Schneider JA,. 1993. Cluster B personality disorder characteristics predict outcome in the treatment of bulimia nervosa. Int J Eat Disord 13 (4): 349-357.
234. Roth AS, Ostroff RB, Hoffman RE,. 1996. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial. J Clin Psychiatry 57 (6): 233-237.
235. Roth KB, Borges G, Medina-Mora ME, Orozco R, Oueda C, Wilcox HC,. 2011. Depressed mood and antisocial behavior problems as correlates for suicide-related behaviors in Mexico. J Psychiatr Res 45 (5): 596-602.
236. Roth-Deri I, Zangen A, Aleli M, et al., 2003. Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens. J Neurochem 84 (5): 930-938.
237. Roth-Deri I, Green-Sadan T, Yadid G,. 2008. Beta-endorphin and drug-induced reward and reinforcement. Prog Neurobiol 86 (1): 1-21.
238. de Ruiter C, Greeven PG,. 2000. Personality disorders in a Dutch forensic psychiatric sample: convergence of interview and self-report measures. J Pers Disord 14 (2): 162-170.
239. Ruocco AC,. 2005. The neuropsychology of borderline personality disorder: a meta-analysis and review. Psychiatry Res 137 (3): 191-202.
240. Ryback RS,. 2004. Naltrexone in the treatment of adolescent sexual offenders. J Clin Psychiatry 65 (7): 982-986.
241. Sansone RA, Lam C, Wiederman MW,. 2010. Road rage: relationships with borderline personality and driving citations. Int J Psychiatry Med 40 (1): 21-29.
242. Schiffer B, Muller BW, Scherbaum N, et al., 2011. Disentangling structural brain alterations associated with violent behavior from those associated with substance use disorders. Arch Gen Psychiatry 68 (10): 1039-1049.
243. Schirmer A, Escoffier N, Zysset S, Koester D, Striano T, Friederici AD,. 2008. When vocal processing gets emotional: on the role of social orientation in relevance detection by the human amygdala. Neuroimage 40 (3): 1402-1410.
244. Schlaepfer TE, Strain EC, Greenberg BD, et al., 1998. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 155 (4): 470-473.
245. Schlosser S, Black DW, Repertinger S, Freet D,. 1994. Compulsive buying. Demography, phenomenology, and comorbidity in 46 subjects. Gen Hosp Psychiatry 16 (3): 205-212.
246. Schmahl C, Bohus M, Esposito F, et al., 2006. Neural correlates of antinociception in borderline personality disorder. Arch Gen Psychiatry 63 (6): 659-667.
247. Schmahl C, Kleindienst N, Limberger M, et al., 2012. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol 27 (1): 61-68.
248. Schultz W,. 2002. Getting formal with dopamine and reward. Neuron 36 (2): 241-263.
249. Semiz UB, Basoglu C, Ebrinc S, Cetin M,. 2007. Childhood trauma history and dissociative experiences among Turkish men diagnosed with antisocial personality disorder. Soc Psychiatry Psychiatr Epidemiol 42 (11): 865-873.
250. Sendula-Jengic V, Boskovic G, Dodig G, Weiner-Crnja M,. 2004. Some aspects of self-destructive behavior in forensic psychiatric inpatients. Psychiatr Danub 16 (1-2): 29-39.
251. Shiels K, Hawk LW, Jr, Reynolds B, et al., 2009. Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 17 (5): 291-301.
252. Shinohara K, Yanagisawa A, Kagota Y, et al., 1999. Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Appl Human Sci 18 (2): 37-42.
253. Shizgal P, Arvanitogiannis A,. 2003. Neuroscience. Gambling on dopamine. Science 299 (5614): 1856-1858.
254. Siever LJ,. 2008. Neurobiology of aggression and violence. Am J Psychiatry 165 (4): 429-442.
255. Slutske WS, Eisen S, Xian H, et al., 2001. A twin study of the association between pathological gambling and antisocial personality disorder. J Abnorm Psychol 110 (2): 297-308.
256. Soderstrom H, Blennow K, Manhem A, Forsman A,. 2001. CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm 108 (7): 869-878.
257. Soloff PH, Pruitt P, Sharma M, Radwan J, White R, Diwadkar VA,. 2012. Structural brain abnormalities and suicidal behavior in borderline personality disorder. J Psychiatr Res 46 (4): 516-525.
258. Sonne S, Rubey R, Brady K, Malcolm R, Morris T,. 1996. Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis 184 (3): 192-195.
259. Stanley B, Sher L, Wilson S, Ekman R, Huang YY, Mann JJ,. 2010. Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord 124 (1-2): 134-140.
260. Steffensen SC, Walton CH, Hansen DM, Yorgason JT, Gallegos RA, Criado JR,. 2009. Contingent and non-contingent effects of low-dose ethanol on GABA neuron activity in the ventral tegmental area. Pharmacol Biochem Behav 92 (1): 68-75.
261. Stein L, Belluzzi J,. 1986. Second messengers, natural rewards, and drugs of abuse. Clin Neuropharmacol 9 (Suppl 4): 205-207.
262. Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K,. 2010. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 16 (6): CD005653.
263. Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K,. 2012. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 8: CD005652.
264. Storey JE, Hart SD, Meloy JR, Reavis JA,. 2009. Psychopathy and stalking. Law Hum Behav 33 (3): 237-246.
265. Streeton C, Whelan G,. 2001. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36 (6): 544-552.
266. Symons FJ, Thompson A, Rodriguez MC,. 2004. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev 10 (3): 193-200.
267. Tang Y, Jiang W, Liao J, Wang W, Luo A,. 2013. Identifying individuals with antisocial personality disorder using resting-state FMRI. PLoS One 8 (4): e60652.
268. Tebartz van Elst L, Hesslinger B, Thiel T, et al., 2003. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry 54 (2): 163-171.
269. Tiihonen J, Kuikka J, Bergstrom K, et al., 1995. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1 (7): 654-657.
270. Tordjman S, Carlier M, Cohen D, et al., 2003. Aggression and the three opioid families (endorphins, enkephalins, and dynorphins) in mice. Behav Genet 33 (5): 529-536.
271. Torgersen S, Lygren S, Oien PA, et al., 2000. A twin study of personality disorders. Compr Psychiatry 41 (6): 416-425.
272. Torgersen S, Czajkowski N, Jacobson K, et al., 2008. Dimensional representations of DSM-IV cluster B personality disorders in a population-based sample of Norwegian twins: a multivariate study. Psychol Med 38 (11): 1617-1625.
273. Vaanholt LM, Turek FW, Meerlo P,. 2003. Beta-endorphin modulates the acute response to a social conflict in male mice but does not play a role in stress-induced changes in sleep. Brain Res 978 (1-2): 169-176.
274. Veit R, Flor H, Erb M, et al., 2002. Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans. Neurosci Lett 328 (3): 233-236.
275. Verona E, Patrick CJ, Joiner TE,. 2001. Psychopathy, antisocial personality, and suicide risk. J Abnorm Psychol 110 (3): 462-470.
276. Viding E, Larsson H, Jones AP,. 2008. Quantitative genetic studies of antisocial behaviour. Philos Trans R Soc Lond B Biol Sci 363 (1503): 2519-2527.
277. Virkkunen M,. 1976. Self-mutilation in antisocial personality (disorder). Acta Psychiatr Scand 54 (5): 347-352.
278. Vollm B, Richardson P, McKie S, et al., 2010. Neuronal correlates and serotonergic modulation of behavioural inhibition and reward in healthy and antisocial individuals. J Psychiatr Res 44 (3): 123-131.
279. Walsh SL, Strain EC, Abreu ME, Bigelow GE,. 2001. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157 (2): 151-162.
280. Weintraub D, Koester J, Potenza MN, et al., 2010. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67 (5): 589-595.
281. Weniger G, Lange C, Sachsse U, Irle E,. 2009. Reduced amygdala and hippocampus size in trauma-exposed women with borderline personality disorder and without posttraumatic stress disorder. J Psychiatry Neurosci 34 (5): 383-388.
282. Westermeyer J, Thuras P,. 2005. Association of antisocial personality disorder and substance disorder morbidity in a clinical sample. Am J Drug Alcohol Abuse 31 (1): 93-110.
283. Wiley MD, Poveromo LB, Antapasis J, Herrera CM, Bolanos Guzman CA,. 2009. Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 34 (5): 1339-1350.
284. Williams TJ, Torres-Reveron A, Chapleau JD, Milner TA,. 2011. Hormonal regulation of delta opioid receptor immunoreactivity in interneurons and pyramidal cells in the rat hippocampus. Neurobiol Learn Mem 95 (2): 206-220.
285. Winchel RM, Stanley M,. 1991. Self-injurious behavior: a review of the behavior and biology of self-mutilation. Am J Psychiatry 148 (3): 306-317.
286. Wise RA,. 2004. Dopamine, learning and motivation. Nat Rev Neurosci 5 (6): 483-494.
287. de Wit H, Enggasser JL, Richards JB,. 2002. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27 (5): 813-825.
288. Yildirim BO, Derksen JJ,. 2012. A review on the relationship between testosterone and life-course persistent antisocial behavior. Psychiatry Res 200 (2-3): 984-1010.
289. Yochelson S, Samenow S,. 1976. The Criminal Personality. Aronson: New York, NY.
290. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ,. 2010. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 1187: 184-207.
291. Zacny JP,. 2010. A possible link between sensation-seeking status and positive subjective effects of oxycodone in healthy volunteers. Pharmacol Biochem Behav 95 (1): 113-120.
292. Zanarini MC, Gunderson JG, Marino MF, Schwartz EO, Frankenburg FR,. 1988. DSM-III disorders in the families of borderline outpatients. J Pers Disord 2 (4): 292-302.
293. Zanarini MC, Frankenburg FR, Yong L, et al., 2004. Borderline psychopathology in the first-degree relatives of borderline and axis II comparison probands. J Pers Disord 18 (5): 439-447.
294. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR,. 2005. The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. J Pers Disord 19 (5): 505-523.
295. Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G, Weinberg I, Gunderson JG,. 2008. The 10-year course of physically self-destructive acts reported by borderline patients and axis II comparison subjects. Acta Psychiatr Scand 117 (3): 177-184.
296. Zanarini MC, Reichman CA, Frankenburg FR, Reich DB, Fitzmaurice G,. 2010. The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study. Int J Eat Disord 43 (3): 226-232.
297. Zanarini MC, Frankenbur FR, Weingeroff JL, Reich DB, Fitzmaurice GM, Weiss RD,. 2011. The course of substance use disorders in patients with borderline personality disorder and Axis II comparison subjects: a 10-year follow-up study. Addiction 106 (2): 342-348.
298. Zapolski TC, Settles RE, Cyders MA, Smith GT,. 2010. Borderline personality disorder, bulimia nervosa, antisocial personality disorder, ADHD, substance use: common threads, common treatment needs, and the nature of impulsivity. Indepen Pract 30 (1): 20-23.
299. Zeki S,. 2007. The neurobiology of love. FEBS Lett 581 (14): 2575-2579.
300. Zhu J, Spencer TJ, Liu-Chen LY, Biederman J, Bhide PG,. 2011. Methylphenidate and mu opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology 61 (1-2): 283-292.
301. Zimmerman M, Rothschild L, Chelminski I,. 2005. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 162 (10): 1911-1918.
302. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ,. 1996. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2 (11): 1225-1229.
303. Zubieta JK, Smith YR, Bueller JA, et al., 2002. mu-Opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci 22 (12): 5100-5107.
304. Zuckerman M,. 1996. The psychobiological model for impulsive unsocialized sensation seeking: a comparative approach. Neuropsychobiology 34 (3): 125-129.